<DOC>
	<DOCNO>NCT00950391</DOCNO>
	<brief_summary>Tacrolimus ( FK506 ) immunosuppressive medication promotes organ allograft survival . It also show enhance nerve regeneration muscle reinnervation animal property previously study patient . Moreover , currently method clinical use speed rate recovery nerve injury . The objective study explore ability tacrolimus benefit treatment patient peripheral nerve injury . To minimize morbidity tacrolimus therapy , phase-specific effect nerve regeneration muscle reinnervation define murine model permit limitation duration therapy . The investigator hypothesize treatment tacrolimus autogenous peripheral nerve reconstruction accelerate nerve regeneration , reduce period denervation improve muscle reinnervation recovery patient peripheral nerve injury . There 2 specific aim : 1 . Determine safety efficacy tacrolimus follow reconstructive nerve surgery double-blind placebo-controlled randomize pilot clinical trial patient severe nerve injury extremities ; 2 . Correlate quality life outcome assessment functional recovery surgical reconstruction patient severe peripheral nerve injury extremity .</brief_summary>
	<brief_title>Enhancement Functional Recovery After Peripheral Nerve Injury With Tacrolimus</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1. deficit upper extremity function MRC grade 02 2. candidate surgical reconstruction 3. 10 month injury 4. ongoing infectious wound heal complication related injury previous surgery otherwise 5. history cancer treat free cancer least 5 year 6. age 1850 7. agree participate study 1. positive HIV hepatitis blood test 2. recent history cancer within past 5 year 3. history severe recurrent infection ( hidradenitis suppurativa ) 4. presence ongoing unresolved infectious concern relate original injury previous surgery ( osteomyelitis , wound infection ) otherwise 5. presence ongoing wound heal problem related injury previous surgery otherwise 6. presence moderate severe liver disease indicate aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , amino alkaline phosphatase , total bilirubin level great upper limit normal ( ULN ) 7. creatinine level ≥ 1.0 mg/dl ULN 8. hemoglobin value &lt; 9.0 mg/dl , white blood cell count &lt; 3,000 cells/mm3 , platelet count &lt; 100,000 platelets/mm3 9. uncontrolled hypertension systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 90 mm Hg screen baseline 10. hyperkalemia ( serum K &gt; ULN ) 11. pancreatitis diabetes mellitus ( fast blood sugar ≥ 110 mg/dl postprandial blood sugar ≥ 160 mg/dl ) history 12. heart disease abnormal electrocardiogram ( ECG ) especially arrhythmia change ST/T previous history 13. history serious drug hypersensitivity 14. age less 18 great 50 15. incarceration prior time consideration enrollment ( participant becomes incarcerated course study exclude )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>peripheral nerve injury</keyword>
	<keyword>peripheral nerve surgery</keyword>
	<keyword>nerve repair</keyword>
	<keyword>nerve graft</keyword>
</DOC>